Author

Monica Z. Montelongo

Observed name: M.Z. Montelongo

Institution: ICON PLC (Ireland)

Observed institution: ICON PLC (Ireland)

ORCID: 0009-0002-3679-7202

Observed ORCID: 0009-0002-3679-7202

OpenAlex ID: A5041865106

Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study

2023 · Joanne L. Blum, Caroline DiCristo, et al. · Breast Cancer Research and Treatment · 15

Real-world quality-of-life of patients with HR+/HER2− advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS

2024 · Gabrielle B. Rocque, Joanne L. Blum, et al. · Breast Cancer Research and Treatment · 10

PDF

Measures of functional status in older patients treated with palbociclib for advanced breast cancer

2023 · Meghan S. Karuturi, Joseph C. Cappelleri, et al. · Journal of Geriatric Oncology · 6

461P Impact of comorbidities on real-world patient-reported outcomes of patients (pts) with hormone receptor-positive human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) enrolled in the POLARIS trial

2023 · J.L. Blum, G. Rocque, et al. · Annals of Oncology · 4

PDF

Abstract P1-18-25: Real-world quality of life (QoL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) treated with palbociclib: A patient-reported outcome (PRO) analysis from POLARIS

2022 · Meghan S. Karuturi, Gabrielle B. Rocque, et al. · Cancer Research · 4

373P Impact of comorbidities on real-world (rw) clinical outcomes of patients (pts) with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) treated with palbociclib and enrolled in POLARIS

2023 · D. Tripathy, J.L. Blum, et al. · Annals of Oncology · 3

PDF

Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study

2025 · Debu Tripathy, Joanne L. Blum, et al. · JCO Precision Oncology · 2

PDF

Abstract P3-01-03: Characterization of neutropenia in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer on palbociclib in a real-world setting: Results from POLARIS

2023 · Debu Tripathy, Joanne L. Blum, et al. · Cancer Research · 2

Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

2022 · Michael Mauro, Ronald Paquette, et al. · Blood · 1

Treatment outcomes and quality of life with palbociclib in patients with advanced breast cancer who also have other medical conditions: a plain language summary of findings from POLARIS

2026 · Debu Tripathy, Joanne L. Blum, et al. · Figshare

Treatment outcomes and quality of life with palbociclib in patients with advanced breast cancer who also have other medical conditions: a plain language summary of findings from POLARIS

2026 · Debu Tripathy, Joanne L. Blum, et al. · Future Oncology

PDF

Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative ( HR +/ HER2 −) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study

2026 · Debu Tripathy, Joanne L. Blum, et al. · Cancer Medicine

Real-world effectiveness of palbociclib plus hormone treatment and its impact on patient quality of life: a plain language summary of findings from POLARIS

2025 · Debu Tripathy, Joanne L. Blum, et al. · Future Oncology

PDF

Relationship of Prior Anticancer Treatments with Palbociclib Clinical Outcomes in Patients with HR+/HER2− Advanced Breast Cancer in Real-World Settings

2025 · Gabrielle B. Rocque, Joanne L. Blum, et al. · Targeted Oncology

PDF

Impact of prior anticancer treatments on palbociclib (PAL) clinical outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) in real-world settings.

2024 · Gabrielle Betty Rocque, Joanne Lorraine Blum, et al. · Journal of Clinical Oncology

Abstract P5-02-22: Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving the Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib: Biomarker Results from POLARIS

2023 · Debu Tripathy, Joanne L. Blum, et al. · Cancer Research

Abstract P3-01-05: Laboratory monitoring in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer treated with palbociclib in a real-world setting: Results from POLARIS

2023 · Gabrielle B. Rocque, Joanne L. Blum, et al. · Cancer Research

Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study

2022 · Jorge E. Cortes, Stuart L. Goldberg, et al. · Blood

Works count: 18

Citation count: 47

H-index: 4

I10-index: 2